Company: MLTX
Filing Date: 2025-04-29
Form Type: 8-K
Source: 0001213900-25-036363
Chunk: 0

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-29
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On April 29, 2025, MoonLake Immunotherapeutics (the “ Company”)
will be posting to its website an investor presentation to be used in the Company’s April 29, 2025 Capital Markets Day event, including
information regarding the Company’s financial position, near-term clinical catalysts and future strategic outlook. The investor
presentation and replays of the webcast will be available on the Company’s website at https://ir. moonlaketx. com.

The information in this current report on Form 8-K shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless specifically so
incorporated.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  MOONLAKE IMMUNOTHERAPEUTICS                               
  Date: April 29, 2025                                      
 ────────────────────────────────────────────────────────────
  By:                              /s/ Matthias Bodenstedt  
  Name:                            Matthias Bodenstedt      
  Title:                           Chief Financial Officer